Business Wire

B2BROKER

16.11.2023 13:11:30 CET | Business Wire | Press release

Share
New B2BinPay v18 Introduces Unified Account System and Massive UI Revisions

B2BinPay, the leading crypto payment processor, has once again raised the bar with its latest v18 solution update. Building upon the success of their previous v17 release, the company has introduced significant advancements for their clients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231116251906/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

B2BinPay v18 update introduces Account Merge - Unifying Merchant and Enterprise Models and streamlining onboarding and business management processes. The update also comes with a fully renewed front-end and enhanced regulatory compliance. (Graphic: Business Wire)

The new release boasts a unified account system, merging the Merchant and Enterprise models and making transaction management easier than ever before. Coupled with a revamped front end and reinforced regulatory compliance, B2BinPay continues to prioritise UX and security in this latest version.

Let’s explore these cutting-edge updates further.

Account Unification

This update brings about a new philosophy in how B2BinPay delivers its services by unifying the two business models (Merchant and Enterprise) into one user-friendly interface.

What exactly does this mean for B2BinPay's clients? It means a more streamlined and integrated experience, as the platform combines both the Merchant and Enterprise account functionality into one user-friendly interface, which means clients can now manage all their transactions within a single, unified system.

But the benefits don't stop there. The account unification also simplifies the registration process, making it easier for businesses to join the platform and use its services immediately. With equal conditions and a single, unified onboarding fee for all types of users, clients have the freedom to choose and transition between services as their business needs evolve without the worry of extra costs or complex administrative processes. With this new approach, businesses can focus on what truly matters – their growth.

Revamped Front-End and Richer Functionality

The v18 release features a redesigned front end that not only aligns with the sleek aesthetic of the B2Broker brand but also offers improved speed and security for users. The core features that have made B2BinPay a favourite among its users have been maintained, ensuring a smooth transition to the updated platform. Here are the sections that have been completely redesigned:

  • Wallets & Transfers

With a sleeker layout and optimised processes, users can quickly navigate through wallets & transfers sections without extra clicks and lengthy loadings. The update streamlines all financial operations, including payouts, bank withdrawals, and exchanges, providing a more seamless and time-saving experience for B2BinPay users.

  • Account Menu

The renewed Account Menu features an intuitive, more user-friendly and secure design. Users can now easily manage their preferences, control API permissions, and customise their profile from one central location. Additionally, the 2FA feature adds an extra layer of security to protect user accounts from unauthorised access.

The Payment Page has also been revamped to reflect the updated design philosophy of B2Broker. This ensures that all financial transactions are carried out in a protected environment.

  • Helpdesk

The updated Helpdesk provides a more streamlined and user-friendly experience for users. With a more defined schedule for multilingual support and new sticker notifications for incoming messages, users can now keep track of their inquiries more efficiently and receive timely responses from the B2BinPay team.

  • Rates Interface

The Rates interface has undergone several upgrades. One of the major changes is that Rates now have richer filtering and favourites options. Additionally, the section can now be accessed directly from the top-level menu instead of being hidden in Wallets.

  • Flexible Invoices

B2BinPay has removed the previous 7-day limit on merchant invoice expiration, allowing for customisation of timelines to fit each business's specific requirements better.

Complying with FATF Travel Rule

The v18 update brings enhanced Travel Rule compliance to the forefront. By partnering with Notabene, a leading provider of Travel Rule solutions, B2BinPay ensures strict adherence to the Financial Action Task Force (FATF) Travel Rules regulations.

The FATF Travel Rule requires VASPs, including B2BinPay, to collect and share personal information in cryptocurrency transactions to prevent money laundering and other unethical practices. New integration equipped B2BinPay with a robust system for detecting suspicious activities and eliminating fraud, providing clients with added peace of mind.

Final Remarks

In light of the growing popularity and acceptance of cryptocurrency, B2BinPay has established itself as a reliable and trustworthy solution in providing efficient crypto payment architecture for businesses. The launch of their v18 update showcases their commitment to constantly improving and expanding their services, staying ahead of market trends and regulatory standards.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231116251906/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye